A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Sicard, Hélène, Bonnafous, Cécile, Morel, Ariane, Bagot, Martine, Bensussan, Armand, Marie-Cardine, Anne
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
Author's View
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570095/
https://ncbi.nlm.nih.gov/pubmed/26405593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1022306
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky